Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little evidence of improving cardiorespiratory fitness, researchers say.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

DR NELLY KAMWALEKenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 diabetes and obesity. Two drugs, Semaglutide and Tirzepatide ...

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval ...